Research Articles | Page 36 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Jan 2019 Leukemia Myelodysplastic Syndromes (MDS)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Nov 2024 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents Oct 2019 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery? Jun 2023 Leukemia & Lymphoma Aplastic Anemia
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Eat and be healthy: nutritional status in myelodysplastic syndromes Jul 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria Dec 2019 Leukemia & Lymphoma Aplastic Anemia
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions Jul 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)